Yüklüyor......
Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran
BACKGROUND: Idarucizumab is a monoclonal antibody fragment that reverses dabigatran anticoagulation. Pharmacokinetics (PK) of idarucizumab have been described in healthy, elderly, or renally impaired (RI) volunteers, but PK data in patients are lacking. OBJECTIVES: This analysis describes the PK of...
Kaydedildi:
| Yayımlandı: | J Thromb Haemost |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6852568/ https://ncbi.nlm.nih.gov/pubmed/31050868 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.14476 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|